Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): a randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial.
- Resource Type
- Article
- Source
- Lancet Respiratory Medicine; Mar2022, Vol. 10 Issue 3, p255-266, 12p
- Subject
COVID-19 CLINICAL trials INFLIXIMAB INTENSIVE care units MULTILEVEL models - Language
- ISSN
- 22132600